International Stem Cell (ISCO) Accounts Payables (2010 - 2026)
International Stem Cell (ISCO) posted quarterly Accounts Payables of $168000.0 for Q4 2025, down 9.68% year-over-year from $186000.0 in Q4 2024, and down 36.6% quarter-over-quarter from $265000.0 in Q3 2025.
International Stem Cell (ISCO) Accounts Payables (2010 - 2026) Analysis & Trends
International Stem Cell (ISCO) has reported Accounts Payables for 16 consecutive years, with $168000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Accounts Payables fell 9.68% year-over-year to $168000.0; the TTM figure through Dec 2025 stood at $168000.0 (down 9.68% YoY), while the FY2025 annual figure was $168000.0, down 9.68% from the prior year.
- Accounts Payables slipped to $168000.0 in Q4 2025 per ISCO's latest filing, from $265000.0 in the prior quarter.
- Across five years, Accounts Payables topped out at $635000.0 in Q1 2022 and bottomed at $168000.0 in Q4 2025.
- Historically, Accounts Payables has averaged $389600.0 across 5 years, with a median of $370500.0 in 2023.
- Annual changes were most pronounced in 2021 — Accounts Payables jumped 56.27% — and 2024, when it tumbled 48.9%.
- International Stem Cell's Accounts Payables stood at $508000.0 in 2021, then plunged by 36.61% to $322000.0 in 2022, then grew by 13.04% to $364000.0 in 2023, then tumbled by 48.9% to $186000.0 in 2024, then retreated by 9.68% to $168000.0 in 2025.
- Business Quant data shows ISCO's Accounts Payables at $168000.0 in Q4 2025, $265000.0 in Q3 2025, and $397000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 108.02 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 428.93 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 35.57 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 622.65 Mn |
| 10 | International Stem Cell | 4.32 Mn | 3.23 Mn | 1.46 Mn | 310,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 310,000.00 |
| Dec 31, 2025 | 168,000.00 |
| Sep 30, 2025 | 265,000.00 |
| Jun 30, 2025 | 397,000.00 |
| Mar 31, 2025 | 457,000.00 |
| Dec 31, 2024 | 186,000.00 |
| Sep 30, 2024 | 321,000.00 |
| Jun 30, 2024 | 377,000.00 |
| Mar 31, 2024 | 360,000.00 |
| Dec 31, 2023 | 364,000.00 |
| Sep 30, 2023 | 303,000.00 |
| Jun 30, 2023 | 331,000.00 |
| Mar 31, 2023 | 351,000.00 |
| Dec 31, 2022 | 322,000.00 |
| Sep 30, 2022 | 378,000.00 |
| Jun 30, 2022 | 477,000.00 |
| Mar 31, 2022 | 635,000.00 |
| Dec 31, 2021 | 508,000.00 |
| Sep 30, 2021 | 611,000.00 |
| Jun 30, 2021 | 469,000.00 |